These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 1096575)

  • 1. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL; Chanelet J; Bastard J; Six P; Emile J
    Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic mechanisms in patients with extrapyramidal disease.
    Chase TN; Shoulson I
    Adv Neurol; 1975; 9():359-66. PubMed ID: 1146660
    [No Abstract]   [Full Text] [Related]  

  • 4. Brain dopamine turnover and the relief of parkinsonism.
    Rinne UK; Marttila R; Sonninen V
    Arch Neurol; 1977 Oct; 34(10):626-9. PubMed ID: 907536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain dopamine turnover and the relief of parkinsonism.
    Rinne UK; Sonninen V; Marttila R
    Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 9. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
    Sweet RD; Wasterlain C; McDowell FH
    Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
    [No Abstract]   [Full Text] [Related]  

  • 10. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
    Callaghan N; Fitzpatrick E; O'Mahony JB
    Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
    Mentenopoulos G; Katsarou Z; Bostantjopoulou S; Logothetis J
    Clin Neuropharmacol; 1989 Feb; 12(1):23-8. PubMed ID: 2713865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
    Extein I; Van Woert M; Roth RH; Bowers MB
    Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actions of dopaminergic agonists in parkinsonism.
    McDowell FH; Sweet R
    Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL; Chalmers RJ; Johnson RH
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
    Feigenson JS; Sweet RD; McDowell FH
    Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J; Chanelet J; Truelle JL; Bastard J
    Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
    [No Abstract]   [Full Text] [Related]  

  • 19. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.